INVESTMENT

UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 10, 2024 - 06:00
UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
Read More

Tags:

Previous Article

Associated Capital Group Sets Registration Date for 2024 Shareholder Designated ...

Next Article

Steel bridge collapses in Vietnam after Typhoon Yagi; 3 rescued

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Some startups and investors are more risk-averse than others

Some startups and investors are more risk-averse than o...

Tomas Kauer - Mode... Sep 14, 2024

Relmada therapeutics CEO acquires shares worth over $395k

Relmada therapeutics CEO acquires shares worth over $395k

Tomas Kauer - Mode... Sep 12, 2024

BMO cuts Canadian National Railway stock target, maintains Outperform rating

BMO cuts Canadian National Railway stock target, mainta...

Tomas Kauer - Mode... Sep 11, 2024